An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
Good news: the FDA has given Mounjaro a new approval to help lower the risk of heart attack and stroke. That’s an additional official use on top of its existing approvals for lowering blood sugar in people with type 2 diabetes. The decision means doctors can now prescribe Mounjaro specifically with the aim of reducing these cardiovascular events, based on evidence submitted to the agency. Mounjaro is the brand name for tirzepatide. It’s a type of medication that acts like hormones your gut makes after you eat. Those hormones normally help control blood sugar and appetite. In plain terms, tirzepatide tells the body to release insulin when it’s needed and to reduce the rise in blood sugar after meals. It’s related to the class of drugs people often hear about for diabetes and weight loss, though tirzepatide is a slightly different, “dual” version that hits two targets instead of one. The FDA decision rests on clinical trial data in people with type 2 diabetes. In those trials, researchers compared patients taking tirzepatide to patients on standard therapy and tracked outcomes like heart attacks and strokes over time. The results showed a lower rate of major cardiovascular events in the tirzepatide group. This wasn’t from a tiny study or from animal work — it’s from randomized clinical trials in humans. That said, the absolute size of the benefit varies by study and patient risk; the approval reflects that regulators judged the reduction in heart events to be meaningful enough to add this indication. Why this matters: heart attacks and strokes are leading causes of death in people with type 2 diabetes. A diabetes medicine that also lowers the risk of those events could change how doctors pick therapies, especially for patients already at high cardiovascular risk. Patients who have had heart disease, or who are at risk because of long-standing diabetes, high blood pressure, or cholesterol, might be candidates for this drug partly for heart protection as well as blood sugar control. There are important caveats and risks. Tirzepatide can cause side effects like nausea, diarrhea, and stomach discomfort; it can also affect gallbladder and pancreas issues in rare cases. Weight loss is common and expected, but rapid weight loss can have its own complications. Long-term effects beyond the trial periods are still being studied. And like other approved drugs, it should be used under a doctor’s supervision; it’s not a general heart drug for people without diabetes unless future studies and approvals say otherwise. Bottom line: Mounjaro (tirzepatide) is now officially approved to lower the risk of heart attack and stroke in people with type 2 diabetes, based on human trial evidence, but patients should weigh benefits and side effects with their doctor.
Source: Yahoo Health